What's breaking now, across thousands of outlets.
(RTTNews) - BridgeBio Pharma (BBIO) reported new real-world data associating acoramidis with improved clinical outcomes versus tafamidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
At 19, Latoya Jones was looking ahead to a future filled with possibilities. When she discovered a small lump in her left breast, the St James native initially dismissed it, convinced that she was too…
WESTERN BUREAU: Health and Wellness Minister Dr Christopher Tufton says today’s children are growing up in a far more challenging environment than previous generations as smartphones, social media and…
[Daily Trust] A health agreement worth $5bn between Nigeria and the United States has raised dust after Ghanaian President, John Dramani Mahama, revealed that his country rejected a similar deal over…
Korean drugmaker HLB has resubmitted its application for U.S. approval of a combination therapy for advanced liver cancer, renewing its push to bring the target treatment to market after addressing…
The Ministry of Public Health (MOPH) has warned against using Gastrozero, an unlicensed dietary supplement containing undeclared pharmaceutical ingredients that could pose a risk to public health.
Health ministry says complaints will be channelled to the nearest district health office for action.
